Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene

Hirose,Koichi; Kozu,Chihiro; Yamashita,Koshiro; Maruo,Eiji; Kitamura,Mizuho; Hasegawa,Junichi; Omoda,Kei; Murakami,Teruo; Maeda,Yorinobu

doi:10.3892/ol.2011.533

March 2012 Volume 3 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March 2012 Volume 3 Issue 3

Full Size Image

Article

Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene

Authors:
- Koichi Hirose
- Chihiro Kozu
- Koshiro Yamashita
- Eiji Maruo
- Mizuho Kitamura
- Junichi Hasegawa
- Kei Omoda
- Teruo Murakami
- Yorinobu Maeda
View Affiliations / Copyright

Affiliations: Department of Pharmacy, Osaka Rosai Hospital, Sakai, Osaka 591-8025, Japan, Department of Surgery, Osaka Rosai Hospital, Sakai, Osaka 591-8025, Japan, Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hiroshima International University, Kure, Hiroshima 737-0112, Japan
Pages: 694-698
|
Published online on: December 22, 2011

https://doi.org/10.3892/ol.2011.533
Expand metrics +

Abstract

In irinotecan (CPT-11)-based chemotherapy, neutropenia and diarrhea are often induced. In the present study, the clinical significance of the concentration ratios of 7-ethyl‑10-hydroxycamptothecin (SN-38) glucuronide (SN-38G) and SN-38 in the plasma in predicting CPT-11‑induced neutropenia was examined. A total of 17 patients with colorectal cancer and wild-type UDP-glucuronosyltransferase (UGT)1A1 gene were enrolled and treated with CPT-11 as part of the FOLFIRI regimen [CPT-11 and fluorouracil (5-FU)]. Blood was taken exactly 15 min following a 2-h continuous infusion of CPT-11. Plasma concentrations of SN-38, SN-38G and CPT-11 were determined by a modified high-performance liquid chromatography (HPLC) method. The median, maximum and minimum values of plasma SN-38G/SN-38 ratios were 4.25, 7.09 and 1.03, respectively, indicating that UGT activities are variable among patients with the wild-type UGT1A1 gene. The plasma SN-38G/SN-38 ratios decreased with an increase in the trial numbers of chemotherapy (r=0.741, p=0.000669), suggesting that CPT-11 treatment suppresses UGT activity, and the low plasma SN-38G/SN-38 ratios resulted in the induction of greater neutropenia. However, in this analysis, 2 clearly separated regression lines were observed between plasma SN-38G/SN-38 ratios and neutropenia induction. In conclusion, UGT activity involved in SN-38 metabolism is variable among patients with the wild-type UGT1A1 gene, and each CPT-11 treatment suppresses UGT activity. One-point determination of the plasma SN-38G/SN-38 ratio may provide indications for the prediction of CPT-11-induced neutropenia and adjustment of the optimal dose, although further studies are required.

View Figures

View References

1	Shimoyama S: Pharmacogenetics of irinotecan: An ethnicity- based prediction of irinotecan adverse events. World J Gastrointest Surg. 2:14–21. 2010. View Article : Google Scholar : PubMed/NCBI
2	Hasegawa Y, Ando Y and Shimokata K: Screening for adverse reactions to irinotecan treatment using the invader UGT1A1 molecular assay. Expert Rev Mol Diagn. 6:527–533. 2006. View Article : Google Scholar : PubMed/NCBI
3	Ratain MJ and Innocenti F: Individualizing dosing of irinotecan. Clin Cancer Res. 16:371–372. 2010. View Article : Google Scholar : PubMed/NCBI
4	Glimelius B, Garmo H, Berglund A, et al: Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 11:61–71. 2011. View Article : Google Scholar : PubMed/NCBI
5	Chabot GG, Abigerges D, Catimel G, et al: Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol. 6:141–151. 1995.PubMed/NCBI
6	Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 33:245–259. 1997. View Article : Google Scholar : PubMed/NCBI
7	Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60:6921–6926. 2000.PubMed/NCBI
8	Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutopenia of irinotecan. J Clin Oncol. 22:1382–1388. 2004. View Article : Google Scholar : PubMed/NCBI
9	Araki K, Fujita K, Ando Y, et al: Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci. 97:1255–1259. 2006. View Article : Google Scholar : PubMed/NCBI
10	Minami H, Sai K, Saeki M, et al: Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A16 and 28. Pharmacogenet Genomics. 17:497–504. 2007.PubMed/NCBI
11	Sai K, Sawada J and Minami H: Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A16 and 28. Yakugaku Zasshi. 128:575–584. 2008.
12	Mathijssen RH, van Alphen RJ, Verweij J, et al: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 7:2182–2194. 2001.PubMed/NCBI
13	Koo DH, Lee JL, Kim TW, et al: A phase II study of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. J Korean Med Sci. 22:98–103. 2007. View Article : Google Scholar : PubMed/NCBI
14	Kurita A and Kaneda N: High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. J Chromatogr B. 724:335–344. 1999.
15	Itoh T, Takemoto I, Hata Y, et al: Determination of the lactone forms and carboxylate forms of irinotecan and its active metabolite, glucuronide by high-performance liquid chromatography. Jpn J Ther Drug Monit. 17:383–389. 2000.
16	Takane H, Miyata M, Burioka N, et al: Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 29:666–668. 2007.PubMed/NCBI
17	Nozawa T, Minami H, Sugiura S, Tsuji A and Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos. 33:434–439. 2005. View Article : Google Scholar
18	Tanaka H, Saito K, Mino K, et al: Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity. Jpn J Cancer Chemother. 36:1505–1509. 2009.PubMed/NCBI
19	Onoue M, Terada T, Kobayashi M, et al: UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol. 14:136–142. 2009.
20	Oostendorp RL, van de Steeg E, van der Kruijssen CM, et al: Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos. 37:917–923. 2009. View Article : Google Scholar
21	Marsh S and Hoskins JM: Irinotecan pharmacogenomics. Pharmacogenomics. 11:1003–1010. 2010. View Article : Google Scholar : PubMed/NCBI
22	Sai K, Saito Y, Maekawa K, et al: Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol. 66:95–105. 2010. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles